Skip to main content
Premium Trial:

Request an Annual Quote

NCI Approves Affymetrix's Terms for GeneChip Sales

Premium

BETHESDA, Md.--Affymetrix, the Santa Clara, Calif., maker of the GeneChip probe array technology, said the US National Cancer Institute has agreed to terms and conditions set forth by Affymetrix that will make the technology accessible to academic and not-for-profit researchers in a manner consistent with the institute's guidelines. Researchers will be able to publish scientific results via traditional and emerging electronic means, collaborate with academic, government, and commercial scientific colleagues, and retain rights to their genetic discoveries. Affymetrix said it will negotiate volume price discounts with each institution separately.

The cancer institute said its concerns about the broad availability of high-throughput molecular analysis technologies to the cancer and general biomedical research community led to its negotiations with Affymetrix. The institute said it will provide administrative supplements to its grantees to purchase DNA equipment, as well as to special programs in research excellence that it supports, in order that comprehensive molecular technologies may be applied to translational cancer research.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.